WaferGen Bio-systems
Investors Count
18Deal Terms
1Funding, Valuation & Revenue
6 Fundings
WaferGen Bio-systems's latest funding round was a Acq - P2P for on May 13, 2016.
WaferGen Bio-systems's valuation in August 2006 was $0.03M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/13/2016 | Acq - P2P | 1 | ||||
2/22/2010 | PIPE - III | |||||
9/21/2009 | PIPE - II | |||||
6/22/2007 | PIPE | |||||
8/10/2006 | IPO | $0.03M |
Date | 5/13/2016 | 2/22/2010 | 9/21/2009 | 6/22/2007 | 8/10/2006 |
|---|---|---|---|---|---|
Round | Acq - P2P | PIPE - III | PIPE - II | PIPE | IPO |
Amount | |||||
Investors | |||||
Valuation | $0.03M | ||||
Revenue | |||||
Sources | 1 |
WaferGen Bio-systems Deal Terms
1 Deal Term
WaferGen Bio-systems's deal structure is available for 1 funding round, including their IPO from August 10, 2006.
Round | IPO |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO |
WaferGen Bio-systems Investors
18 Investors
WaferGen Bio-systems has 18 investors. Takara Bio invested in WaferGen Bio-systems's Acq - P2P funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
5/13/2016 | 5/13/2016 | 1 Acq - P2P | Corporation | Japan | ||
6/22/2007 | 6/22/2007 | 1 PIPE | Investment Bank | Canada | ||
6/22/2007 | 6/22/2007 | 1 PIPE | ||||
Bank | Liechtenstein | |||||
Corporation |
First funding | 5/13/2016 | 6/22/2007 | 6/22/2007 | ||
|---|---|---|---|---|---|
Last Funding | 5/13/2016 | 6/22/2007 | 6/22/2007 | ||
Investor | |||||
Rounds | 1 Acq - P2P | 1 PIPE | 1 PIPE | ||
Board Seats | |||||
Type | Corporation | Investment Bank | Bank | Corporation | |
Location | Japan | Canada | Liechtenstein |
WaferGen Bio-systems Acquisitions
1 Acquisition
WaferGen Bio-systems acquired 1 company. Their latest acquisition was IntegenX - NGS Library Prep Business on January 07, 2014.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/7/2014 | Acquired Unit | 1 |
Date | 1/7/2014 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired Unit |
Sources | 1 |
Compare WaferGen Bio-systems to Competitors
Solidus Biosciences provides data on drug patents, market opportunities, and competitive intelligence, supporting the lifecycle management of drugs from patent inception to expiration. The company serves sectors involved in drug development, patent analysis, and market strategy within the biopharmaceutical domain. It is based in Troy, New York.
Innovate Technologies In Biological Systems works on drug discovery and development within the biotechnology and pharmaceutical sectors. The company provides services such as biological assay development, cell line development, DNA cloning, protein expression, and cell culture media and reagents. Its products support research and development in oncology, CNS disorders, and infectious diseases. It is based in Spain.
The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.
InvivoSciences is a precision medicine company that develops patient-derived 3D micro-tissues for drug discovery. The company provides a platform that includes automated cell and tissue handling, tissue phenotyping assays, and computational biology to identify the safety and efficacy profile of treatments for specific patient groups. InvivoSciences primarily serves the pharmaceutical industry by providing technologies that aim to support the development of treatments for heart failure. It was founded in 2001 and is based in Wauwatosa, Wisconsin.
Shamrock Structures provides drug discovery research services within the pharmaceutical industry. The company offers services such as protein crystallography, medicinal chemistry, and cell biology research to assist in the process from protein target identification to lead compound development. Shamrock Structures serves the pharmaceutical and biotechnology sectors by providing research services that support structure-based drug discovery. It is based in Woodridge, Illinois.
Van Andel Institute is an independent biomedical research institute that conducts fundamental and translational research aimed at developing treatments for cancer, Parkinson's disease, and other health conditions. It offers Ph.D. programs in molecular and cellular biology and provides K-12 educational resources to enhance curiosity and critical thinking in science. It was founded in 1996 and is based in Grand Rapids, Michigan.
Loading...